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Abstract
An enzyme previously identified as -methylacyl-CoA
racemase (AMACR) is overexpressed in high-grade
prostatic intraepithelial neoplasia and in a majority (60–
100%) of prostate cancers (CaPs) as compared with
normal and benign hyperplastic lesions of the prostate,
where it is minimally expressed. This enzyme is required
for the -oxidation of branched-chain fatty acids, which
include phytanic acid and its -oxidation product,
pristanic acid. Interestingly, there is an established
correlation between CaP risk and the consumption of
dairy and beef products, which also contain marked
quantities of these two phytols. In this context, it has also
been reported that sex steroids influence lipogenesis
through the induction of fatty acid synthase in CaP-
derived cell lines and CaP tissues. These findings indicate
a potential role for AMACR and the possible influence of
sex steroids in both the early development and
subsequent progression of CaP. Despite the recent
interest in AMACR as a histological marker for CaP,
little is known about the regulation of this enzyme and its
role in CaP development. To identify potential AMACR-
regulating factors, we treated LNCaP cells (an androgen-
responsive CaP-derived cell line) and NPrEC cells (a
normal prostate basal epithelial cell line) with increasing
concentrations of pristanic acid, phytanic acid, 5-
dihydrotestosterone, and 17-estradiol. Neither the
biologically potent androgen 5-dihydrotestosterone nor
17-estradiol had any apparent effect on AMACR
expression at the protein or transcriptional levels in
either cell line. Conversely, pristanic acid and, to a much
lesser extent, phytanic acid markedly increased AMACR
protein levels selectively in the LNCaP cell line, but not
the NPrEC cell line. However, no change was measured
at the transcriptional level in either cell line. AMACR is
therefore significantly increased at the protein level in
CaP cells, through what appears to be the stabilizing
effect of the same fatty acids that are present at
appreciable concentrations in beef and dairy products,
which have been associated with CaP risk. Our findings
therefore provide a link between the consumption of
dietary fatty acids and the enhanced expression of
AMACR, an enzyme that may play an important role in
genesis and progression of CaP.
Introduction
CaP3 is the most commonly diagnosed cancer in American men
(1). In an attempt to identify genes overexpressed in CaP, thus
gaining insight into the etiology of this form of cancer, several
investigators have recently used high-throughput cDNA screen-
ing techniques (2–7). Xu et al. (7) used a cDNA library sub-
traction method in conjunction with high-throughput microar-
ray screening, resulting in the identification of three genes that
were differentially expressed in normal human prostate as com-
pared with CaP. One of the genes described by Xu et al. (7) as
P504S and previously identified as AMACR was found to be
overexpressed in CaP tissues (7–9). The significance of those
findings was subsequently expanded on by Jiang et al. (10, 11),
who were the first to report that AMACR was significantly
up-regulated in 94–100% of CaP and prostatic intraepithelial
neoplasia lesions tested at the RNA and protein levels. This was
in sharp contrast to the near complete lack of expression in both
benign hyperplastic and normal prostate glands (11). In two
recent reports, Rubin et al. (6) and Luo et al. (12) confirmed
and extended the findings of Jiang et al. (10, 11). In addition,
Luo et al. (12) found strong AMACR expression in 62% of the
metastatic CaP lesions tested and reported that both hormone-
refractory and non-hormone-refractory metastatic lesions were
immunohistochemically positive for AMACR. It is important to
stress that all investigators have demonstrated low to undetect-
able expression of AMACR in normal human prostatic epithe-
lium. Interestingly, it was recently reported that AMACR is
also strongly expressed in several other human carcinomas and
their precursor lesions, implying a basic mechanistic role for
this enzyme throughout the early stages of cancer formation
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involved its expression in the prostate, where it has been touted
as a new molecular marker for prostate cancer (10, 12, 14).
Under normal physiological conditions, AMACR is ex-
pressed at appreciable levels and is transported to both the
peroxisomal and mitochondrial compartments in a variety of
tissues, including liver, kidney, skeletal muscle, gall bladder,
and brain (8, 15–17). AMACR is responsible for the intercon-
version of R-configured -methyl groups found within various
small molecules that contain branched chains, such as phytols
and bile acids, to the S form; a prerequisite for metabolism via
the -oxidation pathway (18, 19). As a result, AMACR is a
required component of the oxidative metabolism and biosyn-
thetic pathways of branched-chain fatty acids and bile acids,
respectively. Pristanic acid, the -oxidation product of phytanic
acid, is one of the more common substrates acted upon by this
enzyme (20–22). Interestingly, phytanic acid is a major com-
ponent of dairy and beef products, resulting in low micromolar
concentrations in the sera of individuals who consume a tradi-
tional Western diet (22–24). This branched-chain fatty acid is
hydrolyzed from chlorophyll by the metabolizing enzymes in
bacterium found in the rumen of animals such as cows and
goats (25–28). As a result, total phytanic acid can reach very
high concentrations in the sera and tissues of these animals (22,
23, 25–29). A correlation has been reported between a diet rich
in dairy and beef products and a risk for CaP (8, 30, 31). Taken
together, these findings indicate a potential role for AMACR in
both the early development and subsequent progression of CaP.
The negligible expression of AMACR in normal prostatic
epithelium, along with its overexpression in CaP, prompted us
to investigate factors that may regulate this enzyme. For rea-
sons mentioned above, along with a recent report that phytanic
acid is capable of inducing a component of the -oxidation
pathway, our investigation focused on the influence of pristanic
and phytanic acids on AMACR expression (32). In addition, we
were interested in determining whether the biologically potent
androgen DHT or E2 has any regulating effect on the expression
of this enzyme. The inclusion of DHT in these studies was
prompted by findings that androgens influence lipogenesis and
enhance the accumulation of neutral lipids through the induc-
tion of fatty acid synthase in AR-positive CaP cell lines (33–
36). E2 was also studied, due to the reported expression of ER-
in both prostatic basal epithelium and CaP, along with the
existence of elements that interact with the ER, such as acti-
vator protein 1, in the promoter region of the rodent AMACR
gene (37–39).
To investigate AMACR regulation in vitro, we chose cell
lines that are highly representative of their cellular tissue coun-
terparts. The LNCaP cell line is derived from lymph node
metastasis and expresses AMACR in a manner comparable
with that seen in primary and metastatic CaP tissues in vivo
(10). As with a majority of primary CaP tissues, this cell line
expresses functional AR and ER- (37, 38). In addition, we
developed an immortalized NPrEC cell line phenotypically
identical to the basal cells that line the human prostatic acinus
(40–42). Basal cells are considered to be the major prolifera-
tive epithelial component of the prostatic acinus and the pur-
ported precursor of secretory cells. This cell line was developed
for these studies to assess AMACR expression in a cell type
believed to play a role in the early stages of CaP development.
Thus, the effects of dietary phytols and sex steroids on the
regulation of AMACR were compared in cell lines that mirror
the in vivo prostate cell types believed to be targets for carcin-
ogens and key participants in neoplastic progression.
Materials and Methods
Cell Culture. The LNCaP, PC3, DU145, and MCF-7 cell lines
were obtained from American Type Culture Collection (Man-
assas, VA) and were of low passage number at the time of each
experiment. The PC3-AR cell line was stably cotransfected
with the full-length wild-type AR and neomycin-resistant
(NEO) gene as reported previously (43). DU145, PC3, and
MCF-7 cell lines were all grown in DMEM:Ham’s F-12 (In-
vitrogen, Carlsbad, CA). LNCaP cells were grown in RPMI
1640 (Invitrogen). The normal prostate epithelial NPrEC cells
were obtained from Clonetics-BioWhittaker, Inc. (Walkers-
ville, MD), and immortalized by the addition of a retroviral
vector expressing human papilloma virus E6/E7 open reading
frames as described previously (44). This NPrEC cell line was
grown on the recommended PrEGM media supplied by Clo-
netics-BioWhittaker, Inc. The phenotype of these cells was then
determined by comparing the pattern of protein markers with
cellular counterparts in tissues (see “Immunocytochemistry”).
All cells were seated on cell culture-treated T-75 vented or
24-well Falcon plates (BD Biosciences, Bedford, MA) and
cultured at 37°C under 95% humidity and 5% CO2 in 10 or 1.0
ml (respectively) of the media recommended by American
Type Culture Collection containing 5% FBS (Invitrogen) for
24 h and changed to 5% charcoal-stripped serum (Sigma, St.
Louis, MO) or serum-free medium supplemented with insulin
transferrin selenium (ITS) (BD Biosciences) for 24 h before
treatment. For all experiments, compounds were brought up in
DMSO and diluted 1000 in media to the appropriate concen-
trations. Cells were treated with DHT, E2, and phytanic acid
(Sigma); pristanic acid (Lordan Lipids, Malmo, Sweden); and
bicalutamide (CAS) extracted in DMSO from 50-mg tablets
(Astra Zeneca, Wilmington, DE).
Immunoblotting. Western blot analysis was performed on
total cell lysates that were prepared and diluted in M-Per
reagent (Pierce, Rockford, IL) to a concentration of 2 g/l.
Protein quantification was determined with BCA reagent
(Pierce) and compared with a standard curve of bovine albumin
on a Quant UV-visible plate reader at 590 nm (BIO-TEK
Instruments, Winooski, VT) with KC-Junior software. Aliquots
of 50.0 g of cell extract were separated on 10% SDS-PAGE
Tris-HCl Ready Gels (Bio-Rad, Hercules, CA) at 80 V for 2.5 h
and electroblotted to a polyvinylidene difluoride membrane
(Millipore, Bedford, MA). Membranes were blocked in 5%
milk PBST for 1 h, washed in PBST, and incubated with one of
the following primary antibodies: anti-AMACR rabbit mAb at
a 1 g/ml dilution or anti--actin rabbit polyclonal antibody at
a 1:500 dilution (Sigma) for 1 h while shaking at 4°C in a sealed
Kapak bag (Kapak, Minneapolis, MN). This was followed by
incubation with a horseradish peroxidase-linked secondary an-
tirabbit antibody (Amersham Biosciences, Piscataway, NJ) at a
1:10,000 dilution for 1 h. Detection was performed using ECL-
plus reagent (Amersham Biosciences) according to the manu-
facturer’s instructions and visualized on a STORM 840 imag-
ing system (Amersham Biosciences) at 900 V in blue
fluorescence mode. Relative quantification was carried out with
Kodak 1D 3.5 software (Eastman Kodak Co., New Haven, CT).
Immunocytochemistry. Treated and untreated NPrEC,
LNCaP, PC3, and DU145 cells were harvested after 36 h of
incubation. The cells were washed with HBSS and trypsinized.
After trypsinization, a neutralizing solution was then added, and
cells were transferred into 15-ml centrifuge tubes. Cells were
then centrifuged at 1000 rpm for 5 min. After decanting the
fluid, 10% buffered formalin was added to the cell pellet
formed at the bottom of the tube. After 12 h of fixation, the
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pellet was removed with a spatula, routinely processed, and
embedded in paraffin. Approximately 10 unstained sections
were cut at 4–6 m and attached to glass slides. Slides were
then deparaffinized in xylene for 5 min. Sections were then
rehydrated by briefly immersing them in graded alcohols and,
finally, in water. Antigen retrieval was carried out with 0.1 M
citrate buffer in an 880 W microwave for 10 min. After rinsing,
endogenous peroxidase activity was blocked with 3% hydrogen
peroxide. The sections were rinsed again, and nonspecific sites
were blocked with a blocking protein (Ventana, Tuscon, AZ).
Sections of NPrEC cells were immunostained using a Techmate
1000 automated immunostainer (Ventana). For these studies,
the following antibodies were used: mouse high molecular
weight cytokeratin mAb 34E 12 at a dilution of 1:50 (HMWC;
Dako, Carpenteria, CA); mouse P63 mAb (Dako); mouse AR
mAb at a dilution of 1:80 (Biogenix Laboratories, San Ramon,
CA); and mouse ER- mAb at a dilution of 1:50 (Ventana). For
AMACR immunostaining we used the rabbit mAb P504S at a
dilution of 0.5 g/ml (Corixa Corp., Seattle, WA). The same
secondary antibodies and the Ventana staining procedure were
then used to stain five paraffin-embedded sections of normal
prostate tissue. ER- immunostaining was carried out manually
using the GC17, a rabbit polyclonal antibody (Biogenex), as
described previously (45). For all immunostains, primary anti-
bodies were incubated with each section for 45 min. After brief
buffer washes, the sections were incubated with a mixture of
biotinylated antirabbit IgG or antimouse IgG/IgM (Ventana) for
30 min. Sections were then incubated in an avidin/peroxidase
complex (Ventana) for 30 min and, after rinsing, treated with
diaminobenzidine to visualize the end product. Finally, sections
were counterstained with hematoxylin. Sections of normal hu-
man prostate or normal breast tissue served as positive controls.
Negative controls were the substitution of the primary antibod-
ies with an appropriate class-matched serum.
Real-Time Reverse Transcription-PCR. Total RNA was ex-
tracted with TRI reagent (Sigma) according to the manufactur-
er’s instructions. RNA quantification and integrity were meas-
ured by UV spectrophotometry by the 260 nm/280 nm method
and denaturing gel electrophoresis, respectively. Potential con-
tamination by genomic DNA was removed by DNase I treat-
ment, in which 1 g of total RNA was incubated with RQ1
RNase-free DNase (Promega, Madison, WI) in a total reaction
volume of 10 l at 37°C for 30 min, followed by termination
with the addition of 1 l of the DNase stop solution provided
by the vendor. The reverse transcription reaction was carried
out with TaqMan reverse transcription reagents (Applied Bio-
systems, Foster City, CA) according to the manufacturer’s
instructions in a reaction containing random hexamers prepared
in a reaction volume of 60 l and 1 g of DNase-treated RNA.
Real-time PCR was carried out, using a previously published
primer set, on 5 l of the reverse transcription reaction mixture
along with SybrGreen 2 PCR master mix (Applied Biosys-
tems) in the iCycler thermocycler (Bio-Rad; Ref. 13). The
cycling conditions comprised an initial denaturing step of 94°C
for 4.5 min; followed by 50 cycles at 94°C for 30 s, 60°C for
30 s, and 72°C for 45 s; with a final extension at 72°C for 10
min. Experiments were performed in triplicate for each treat-
ment.
Determination of Total Pristanic and Phytanic Acid Levels
in Serum by GC-MS. The serum concentrations of pristanic
and phytanic acids were determined by gas chromatography-
electron capture negative ion mass spectrometry using a mod-
ified form of the method reported by Stellaard et al. (46). Serum
(100 l) was mixed with 40 l of iso-octane containing 100 ng
of D3-pristanic acid and 1 g of D3-phytanic acid internal
standards (Lorodan Lipids), 160 l of n-hexane, and 2.0 ml of
0.5 n HCl in acetonitrile and heated at 100°C for 45 min to free
the lipid-bound fatty acids. The fatty acids were extracted into
2.0 ml of n-hexane, and the solvent was evaporated. The fatty
acids were then converted to their PFBz esters by reaction with
a solution containing 10 l of triethylamine and 5 l of PFBz
bromide in 50 l of acetonitrile at room temperature for 15 min.
Acetonitrile (200 l) and n-hexane (1.0 ml) were added to the
reaction mixture, and after vigorous mixing and separation of
the phases, the n-hexane phase was transferred to an autosam-
pler. The solvent was evaporated under a stream of nitrogen,
and the PFBz fatty acids were redissolved in 0.5 ml of n-hexane
for GC-MS injection. GC-MS was performed using a Waters
Quattro-II triple quadrupole mass spectrometry system
equipped with an Agilent 6890 GC and an Agilent 7683 au-
tosampler (Agilent, Palo Alto, CA). One l of samples and
standards were injected in the splitless mode onto a 0.25 mm
30 m DB-23 (phase thickness, 0.25 m) fused silica capillary
column with He as the carrier gas at 0.8 ml/min. The column
temperature was programmed from 165°C to 240°C at 5°C/
min. Elution peaks for PFBz pristanic and phytanic acids were
at 9.1 and 10.5 min, respectively. Electron capture negative ion
ionization was performed using methane as the moderator gas
at 3e-4 mBar with the electron energy at 50 eV and the emission
current at 300 A. Selected ion monitoring was performed at
m/z 297.3 (pristanic acid), 300.3 (D3-pristanic acid), 311.3 (phy-
tanic acid), and 314.3 (D3-phytanic acid). Concentrations for
both analytes were measured from the ratio of selected ion plot
peak area of each analyte to its internal standard in comparison
with three-point calibration curves run with the samples.
Cytotoxicity and Cell Number Assays. Cells were seated at
10,000 cells in 24-well plates. Cytotoxicity was quantified by
the release of LDH, whereas cell number was related to the
reduction of the tetrazolium dye MTS in the same assay plate.
After the specified treatments, 100 l of media was transferred
to a 96-well plate for the quantification of LDH as per the
manufacturer’s instructions, and normalized between non-
treated controls and cell lysed by three repetitions of freeze and
thaw. The cell media were then refreshed with added MTS
reagent as per the manufacturer’s instructions and measured at
590 nm after approximately 2 h. All values were normalized to
nontreated controls.
Results
Immunocytochemical Characterization of NPrEC Cells.
NPrEC cells, grown without the addition of DHT, E2, or fatty
acids, were found to stain strongly positive for HMWC, P63,
and ER- (Fig. 1, A, C, and E, respectively). In sharp contrast,
AR, AMACR (Fig. 1, G and I), and ER- (data not shown)
were undetectable by IHC analysis. Basal cells in tissue sec-
tions of morphologically normal human prostate revealed iden-
tical staining with the selective antibodies (Fig. 1, B, D, F, H,
and J) to that observed in the NPrEC cell line. Thus, NPrEC
cells expressed precisely the same pattern of phenotypic im-
munocytological markers that characterizes human basal cells
in normal prostatic tissues (41, 45, 47, 48).
AMACR Expression in Untreated Prostate Cell Lines. The
prostate cancer cell lines DU145, PC3, PC3-AR (AR-trans-
fected PC3), LNCaP, the breast cancer MCF-7 cell line, the
normal immortalized NPrEC basal cell line, normal prostate
tissues, and CaP tissues were all subjected to Western blot
analysis (Figs. 2, d and e). Only the LNCaP cell line expressed
AMACR at both the transcriptional (Fig. 2f) and protein levels,
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similar to that found in CaP tissues. The NPrEC cells expressed
AMACR at a level approximately 10–12-fold less than that of
the LNCaP cell line at the both the transcriptional (Fig. 2f) and
protein levels (Fig. 2e). The normal prostate tissues used in this
study did not express measurable levels of AMACR (Fig. 2e).
However, similar studies have illustrated that normal prostate
tissues often express levels of AMACR approximately 9-fold
less than that of CaP tissues, in agreement with values observed
for the LNCaP and NPrEC cell lines (6, 10). The IHC findings
paralleled the results of the immunoblot studies in that AMACR
was strongly expressed in LNCaP cells (Fig. 1H; Fig. 2, a and
e). In contrast, only scattered immunopositive cells (2–3
cells/1000 cells) were observed in PC3 cells, and no staining
was present in DU145 cells (Fig. 2, b and c). Whereas AMACR
protein was weakly detected by Western analysis (carried out
on 50 g of total protein per lane) from NPrEC cell lysate, no
immunostaining was observed (Fig. 1H). This was also the case
for basal cells in tissue sections, which were negative for
AMACR staining. In marked contrast, CaP in tissue sections
and LNCaP cells stained strongly with both Western blot and
IHC analysis techniques.
To establish appropriate media for additional studies in the
LNCaP cell line, the following four media variations were
studied: serum-free media with and without added ITS supple-
ment (data not shown); along with media containing either FBS
or charcoal-stripped CS (Fig. 3; Refs. 23, 25, 27, 32, and
49–51). Although it is known to contain significant levels of
steroid hormones, FBS has been shown to contain low levels of
phytanic acid, presumably due to an inability to cross the
placenta (32). On the other hand, CS is known to contain high
concentrations of phytanic acid, which may not be adequately
stripped with the standard dextran-coated charcoal methods
commonly used to remove steroids (45, 28, 32). In this respect,
charcoal-stripped FBS is not readily available for purchase,
whereas charcoal-stripped CS is available from various sources.
For this reason, a single lot of FBS and charcoal-stripped sera
were analyzed for total pristanic and phytanic acid content by
GC-MS. The FBS tested contained phytanic acid at concentra-
tions similar to previously published reports of 0.83 M,
whereas the concentration of pristanic acid was 0.17 M (32).
Charcoal-stripping the calf sera appeared to decrease phytanic
acid concentrations considerably to 2.2 M, as compared with
the reported values for non-stripped bovine sera, which range
from 19 to 231 M (32). Pristanic acid concentrations were
found to be nearly 10-fold lower than phytanic acid in the
stripped CS at 0.24 M. Interestingly, LNCaP cells grown on
any one of the media described expressed similar levels of
AMACR, with the exception of cells grown on FBS, which
showed a 3-fold decline in message and protein expression.
However, due to the presence (albeit at low levels) of phytanic
acid in both the stripped CS and FBS, we chose to complete the
phytol-related studies in a defined medium. In addition, for all
other comparative studies involving Western blot analysis,
equal amounts of protein were added to each well, and -actin
co-blotting (data not shown) was used to further assure equal
loading.
Androgen Treatment. LNCaP cell cultures were supple-
mented with 5 nM DHT and/or CAS in charcoal-stripped CS for
36 h. Both AMACR and PSA were analyzed by Western blot
and real-time reverse transcription-PCR analysis. PSA was
induced by DHT at both the protein and transcriptional level
Fig. 1. NPrEC cells were immunostained for HMWC, P63, ER-, AR, and AMACR on A, C, E, G, and I, respectively, and compared with corresponding tissue sections
of normal human prostatic acinus immunostained with the same antibodies on B, D, F, H, and J. For example, strong cytoplasmic staining of NPrEC cells and tissue prostatic
basal cells is evident for HMWC (A and B), whereas only nuclear staining is present with P63 (C and D) and ER- (E and F). In contrast, immunostaining is absent for
AR in NPrEC cells (G) and in tissue basal cells (H), but nuclear staining for the receptor is present in overlying tissue secretory cells (H). AMACR immunostaining is
completely absent in NEPrEC cells (I) and both secretory and basal cells in prostate tissue sections (J). The bar on each panel represents 6–8 m, and all sections were
counterstained with hematoxylin.
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and was blocked by the addition of CAS. In contrast, no
measurable increase in AMACR was observed with these treat-
ments (Fig. 4). The NPrEC cell line was not treated with DHT
because it was found to be free of AR by immunohistochem-
istry.
Estrogen Treatment. Both the LNCaP and NPrEC cell cul-
tures were supplemented with E2 because both cell lines ex-
press ER- and therefore have the potential for ER-mediated
regulation of AMACR. Increasing concentrations of E2 ranging
from 100 pM to 10 nM were used with no effect observed on
AMACR expression at the protein or transcriptional level
(Fig. 5).
Treatment with Phytanic and Pristanic Acids. Both the
LNCaP and NPrEC cell cultures were supplemented with phy-
tanic acid and its -oxidation product, pristanic acid (22).
Supraphysiological concentrations of phytanic acid are known
to induce cytotoxicity in a variety of cell types (25, 52). There-
fore, toxicity and cell number were determined by LDH release
Fig. 2. Shown are the IHC results from LNCAP, PC3, and DU145 cells (a–c, respectively) and the immunoblotting (d) results on the cell lines noted with an antibody
directed toward AMACR. a, strong and uniform cytoplasmic staining for AMACR is visualized in this pellet of LNCaP cells, compared with the absence of AMACR
staining in NPrEC cells (Fig. 1I). b, positive immunostaining was consistently present in only a few (2–3 per 1000) PC3 cells. c, no staining for AMACR was observed
in the DU145 pellet. d, 1.0 ng of recombinant AMACR protein and 15 g of total cell lysate from each cell line (breast cancer cell line MCF-7 and prostate cancer cell
lines PC3-AR, PC3, DU145, and LNCaP). e, 15 g of total cell lysate from each (LNCaP, CaP tissue, NPrEC, and normal prostate tissue). f, AMACR transcript levels
(average of n  2); results are normalized to NPrEC cells.
Fig. 3. LNCaP cells were grown in serum-free media (SFM), FBS, or charcoal-
stripped sera (CSS) for 36 h. Top, AMACR mRNA levels were normalized to cells
grown in FBS. Bottom, AMACR protein levels were measured by Western
analysis in the media described.
Fig. 4. LNCaP cells were treated with 5 nM DHT, 5 M CAS, or both for 36 h.
Top, AMACR and PSA mRNA levels were normalized to nontreated (NT)
controls. Bottom, Western analysis of AMACR and intracellular PSA protein
levels in LNCaP cells after the treatments described.
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and MTS reduction (respectively) after treatments with increas-
ing amounts of phytanic acid for 48 h. Phytanic acid was found
to induce nearly 100% cell death at 10 M in NPrEC cells and
20–50% cell death at 25–50 M in LNCaP cells grown in
serum-free media (Fig. 6). These findings indicate that the
immortalized basal cell line is much more susceptible to the
toxic effects of phytanic acid than the prostate cancer cell line.
Consistent with what would be expected of a cytotoxic mech-
anism, the number of cells as measured by the MTS method
was inversely correlated with LDH release. Interestingly, there
was a significant increase in cell number in both cell lines at
only 48 h in the high nanomolar range, at a concentration that
did not cause cytotoxicity (Fig. 6).
Cultured LNCaP cells were supplemented with 25 M
phytanic acid at 24, 36, and 48 h. The level of AMACR was
maximally increased at the protein level after 36 h by nearly
3-fold, with no effect at the transcriptional level (Fig. 7a). Both
the LNCaP and NPrEC cell lines were therefore treated for a set
time period of 36 h with increasing concentrations of pristanic
and phytanic acids from 100 nM to 3 M for NPrEC and up to
50 M for LNCaP cells. AMACR was maximally increased in
the LNCaP cell line at the protein level by approximately 3-fold
in the presence of 25 M phytanic acid and by 5–6-fold with 25
M pristanic acid. In marked contrast there was no effect by
either phytol at the transcriptional level (Fig. 7b). Conversely,
AMACR was slightly decreased at the protein level in NPrEC
cells at the highest concentration of 3 M, but there was no
measurable change at the transcriptional level with both phy-
tanic and pristanic acids (Fig. 8).
Discussion
The recent observation that AMACR is significantly up-regu-
lated in nearly all CaP and prostatic intraepithelial neoplasia
lesions has prompted speculation regarding the role of this
protein, if any, in the initiation or progression of these lesions
(14). To address this question, we have searched for and iden-
tified two cell lines that could serve as in vitro models for CaP
tissues (LNCaP) and normal prostatic basal epithelium
(NPrEC). We first compared the level of AMACR expression
at both the transcriptional and protein levels in a number of cell
lines including DU145, PC3, PC3-AR, and LNCaP with that of
normal and CaP tissues. LNCaP cells were found to be the only
established CaP cell line that expressed AMACR at levels
similar to those of CaP tissues. In addition, we have recently
established an immortalized prostate epithelial cell line that was
shown to express prototypic markers identical to those found in
normal basal epithelial cells (41, 45, 47, 48). Whereas the
NPrEC cells expressed very low levels of AMACR, as meas-
ured by immunoblot analysis, this protein was undetectable by
IHC staining in both the normal cell line and normal tissues
studied.
The addition of varying concentrations of DHT or E2 to
the culture media had no effect on AMACR expression in either
cell line. While we were finalizing these experiments, a con-
firming report was published indicating that AMACR expres-
sion is not responsive to androgen (53). To our surprise, AM-
ACR was highly expressed in LNCaP cells, even in growth
Fig. 5. LNCaP and NPrEC cells were treated with in-
creasing levels of E2 for 36 h. Left panels, Western anal-
ysis of AMACR on total cell extracts from prostate-
derived cell lines. Right panel, AMACR mRNA levels
were normalized to nontreated (NT) controls.
Fig. 6. LNCaP and NPrEC cells were treated with increasing levels of phytanic
acid for 48 h. Cell number was quantified by the reduction of MTS, and
cytotoxicity was assessed by the release of LDH into the media. All values were
normalized to nontreated (NT) controls. , P  0.05.
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factor-starved media, indicating that insulin, the primary
growth factor in defined media, was not required to maintain
expression of this gene. However, it is noteworthy that an
unknown factor(s) in FBS consistently down-regulated AM-
ACR by approximately 3-fold at both the transcriptional and
protein levels in LNCaP cells. Our data therefore indicate that
AMACR is primarily expressed in a constitutive manner, not
influenced by systemic hormones, in prostate cancer cells.
Because phytanic acid and its -oxidation product, pris-
tanic acid, are the common prosubstrate/substrate for this en-
zyme, respectively, we investigated the possibility that these
fatty acids play a role in regulating AMACR expression (21,
22). Our interest in this possibility was prompted by past
reports indicating that these fatty acids are present at high levels
in beef and dairy products and that consumption of these foods
is associated with an increased risk for CaP (22–24, 30, 31, 54).
The addition of pristanic and phytanic acids to the LNCaP cell
line resulted in a marked increase in AMACR expression at the
protein level, with no effect at the transcriptional level. Most
interestingly, AMACR was unaffected by similar treatments in
the NPrEC cell line. This type of response in LNCaP cells is
indicative of a substrate-induced protein stabilization mecha-
nism reported for other metabolizing enzymes such as cyto-
chrome P450 2E1 (55). In agreement with this hypothesis, we
found that 1–3 M of the substrate pristanic acid enhanced
AMACR protein to a greater extent than phytanic acid at
concentrations between 25 and 50 M. This indicates either that
the prosubstrate is capable of weak interaction with AMACR or
that the -oxidation pathway is significantly active in LNCaP
cells, such that an appreciable level of pristanic acid is pro-
duced.
From these studies alone, it would be difficult to rule out
the possibility that phytanic acid can affect AMACR expression
in the NPrEC cell line. This is because 10 M phytanic acid
induced nearly 100% cell death in this cell line, well below that
required to enhance AMACR in LNCaP cells. However, pris-
tanic acid was also unable to enhance AMACR expression in
the NPrEC cell line at 1.0 M, but this concentration was
sufficient to enhance AMACR expression in LNCaP cells.
Moreover, we found that LNCaP cells were at least 20-fold less
sensitive to the cytotoxic actions of phytanic acid than the
NPrEC cell line. It may be inferred from this that AMACR acts
in part as a survival factor. This may be supported in part by
previous reports that phytanic acid is cytotoxic; as a result,
cellular defenses have evolved in select tissues to help keep this
molecule out of the cell (56–58). For example, fatty acid-
binding proteins, which are induced by phytanic acid through
peroxisome proliferator-activated receptor , act in a protective
fashion by binding to, thus inhibiting the cytotoxic effects of
this fatty acid (56–58). In this respect, fatty acid-binding pro-
tein V has recently been reported to be expressed at appreciable
levels in CaP tissues, thus indicating a need to protect against
Fig. 7. LNCaP cells were treated with 25 M phytanic
acid for varied time points. a, left panel, Western analysis
of AMACR carried out on total cell extracts. a, right
panel, AMACR mRNA levels were normalized to non-
treated controls. LNCaP cells were then treated with in-
creasing levels of either phytanic or pristanic acid for
36 h. b, left panels, Western analysis of AMACR was
carried out on total cell extracts. b, right panel, AMACR
mRNA levels were normalized to nontreated controls.
Fig. 8. NPrEC cells were treated with increasing levels
of either phytanic or pristanic acid for 36 h. Left panels,
Western analysis of AMACR carried out on total cell
extracts. Right panel, AMACR mRNA levels were nor-
malized to nontreated (NT) controls.
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this fatty acid in the prostate (59, 60). Finally, it is important to
note that phytanic acid also induced a minor yet significant
increase in cell number in both cell lines at high nanomolar
concentrations within as little as 48 h. Whereas this observation
has not been reported previously, it is not entirely surprising,
considering the multitude of biological effects that branched-
chain fatty acids including phytanic and pristanic acid have
been reported to exhibit (24, 52, 61–65).
In summary, AMACR protein, but not its transcript, is
expressed at significantly higher levels in CaP cells as com-
pared with NPrEC cells through a mechanism unaffected by
common serological factors including DHT, E2, and insulin.
The level of AMACR protein is further enhanced specifically in
CaP cells by fatty acid substrates found in foods associated with
an increased risk for CaP. These same fatty acids, while having
no observed effects on AMACR expression in NPrEC cells, are
capable of inducing proliferative and cytotoxic effects at phys-
iological and supraphysiological concentrations, respectively.
Although these studies do not rule out the possibility that
normal prostatic “secretory” cells may respond to treatments
with pristanic acid, these results indicate that enhanced metab-
olism of branched-chain fatty acids, such as pristanic acid, may
contribute to the progression of CaP. Hence, therapeutic strat-
egies aimed at selectively inhibiting this pathway in CaP may
prove effective in the treatment and prevention of this disease.
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